Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Reunion Neuroscience Inc T.REUN

Healthcare Biotechnology
Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a... see more

Recent & Breaking News (TSX:REUN)

Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference

GlobeNewswire April 3, 2024

Reunion Neuroscience Inc. to Participate in October Investor Conferences

GlobeNewswire October 5, 2023

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression

GlobeNewswire September 18, 2023

Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement

GlobeNewswire August 1, 2023

Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement

GlobeNewswire July 14, 2023

Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement

GlobeNewswire July 13, 2023

Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

GlobeNewswire June 29, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCE, AAIC, GRNA, REUN

PR Newswire June 13, 2023

Moore Kuehn Encourages WTT, DM, AAIC, and REUN Investors to Contact Law Firm

PR Newswire June 6, 2023

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Reunion Neuroscience Inc. Buyout

Newsfile June 1, 2023

REUN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reunion Neuroscience Inc. Is Fair to Shareholders

Business Wire June 1, 2023

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

GlobeNewswire June 1, 2023

Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 25, 2023

Reunion Neuroscience Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

GlobeNewswire April 25, 2023

Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors

GlobeNewswire April 3, 2023

Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting

GlobeNewswire March 27, 2023

Reunion Neuroscience (TSX:REUN) files lawsuit against Mindset Pharma (CSE:MSET)

John Ballem  March 14, 2023

Reunion Neuroscience Files Lawsuit Against Mindset Pharma

GlobeNewswire March 13, 2023

Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference

GlobeNewswire March 7, 2023

Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results

GlobeNewswire February 14, 2023